# Cagrilintide

> Cagrilintide is an investigational long-acting amylin receptor agonist studied both alone and in combination with GLP-1 agonists for weight management. As monotherapy, trials have reported meaningful but generally more modest average weight reduction than the leading combination and multi-agonist therapies. It has not received independent regulatory approval and is most often studied as part of combination products such as CagriSema. Evidence for cagrilintide as a standalone therapy remains more limited than for combination use.

- URL: https://www.lifeconverted.com/peptides/cagrilintide
- Also known as: AM833
- Primary category: Weight Management
- Effectiveness rank: #6 in Weight Management
- Evidence level: Moderate evidence
- Route: Subcutaneous
- Dose range: 0.3-4.5 mg
- Dose tiers: low 0.3 mg; moderate 2.4 mg; high 4.5 mg
- Half-life: Approximately 7 days, consistent with once-weekly dosing
- Timing: Weekly · same day, any time
- Cycle: Continuous use with titration over several months in trial protocols on, Not established outside of trial settings off
- Storage: Refrigerate at 2-8°C; protect from light; do not freeze.

## Mechanism of action

Cagrilintide activates amylin receptors, mimicking the pancreatic hormone amylin, which slows gastric emptying and contributes to satiety signaling in the brain. Its long-acting formulation is designed to support once-weekly dosing, and its mechanism is complementary to but distinct from GLP-1 receptor agonism.

## Reported benefits

- Associated with meaningful average weight loss as monotherapy in trials
- Once-weekly dosing schedule
- Complementary satiety mechanism to GLP-1 agonists
- Studied as a component of combination therapies with additive effects reported

## Reported side effects

- Nausea, vomiting, and diarrhea, especially during titration
- Decreased appetite
- Injection-site reactions
- Long-term monotherapy safety data remain limited

## Common protocols

- Trial-based step-up titration schedule
- Once-weekly subcutaneous injection with site rotation

## Stacking notes

Most commonly studied in combination with GLP-1 receptor agonists (e.g., semaglutide); such combinations should only occur under medical supervision or within trial protocols.

---

Educational information only, not medical advice. Full disclaimer: https://www.lifeconverted.com/disclaimer